Serotonin Revived as a Possible Target for Autism TreatmentsJessica Wright
The exact pathophysiology of the neurodevelopment disorder of autism is not clear and there is not any curative approach for it. There is only one FDA-approved medication for its management. Therefore, providing of novel treatments is highly required. The hypofunction of GABAergic system and glutam...
Nearly half of fragile X patients are also diagnosed with autism. Zhao's new study, in the journalNature Neuroscience, shows that when mutated, the fragile X gene fails to produce its unique protein. As a result, subcellular units called mitochondria inside developing neurons are malformed, so ...
The authors add that even as new interventions are developed for anxiety disorders, recent discovery of genetic variants associated with efficacy of existing behavioral treatments suggests new ways to tailor their use. Examples such as this and others provide strong bases for hope that ...
Although such a potential treatment is years away, the current study is a major advance for conditions that today lack treatments, Zhao says. "Human neuroscience seems to get more complex all the time, but I feel we've established a foothold that allows us to see the true source of difficu...
(2018). Translating person-specific network models into personalized treatments: Development and demonstration of the dynamic assessment treatment algorithm for individual networks (DATA-IN). Psychotherapy and Psychosomatics, 87, 249–251. Article PubMed Google Scholar Ryan, O., & Hamaker, E. L. ...
Background Autism spectrum disorder (ASD) is one of a number of neurodevelopmental disorders that display sexual di- morphism, occurring more frequently in males, which affect brain structure, gene expression, pathways, function, and ultimately behaviors that will require individualized treatments [1–...
PPARγ agonists: potential treatment for autism spectrum disorder by inhibiting the canonical WNT/β-catenin pathway. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0131-4. Vallée A, Lecarpentier Y, Vallée J-N. Targeting the canonical WNT/β-catenin pathway in cancer treatment ...
Researchers at the Del Monte Institute for Neuroscience at the University of Rochester are coming closer to finding a possible target for treatingneuropsychiatric disorderslike schizophrenia and autism during this time of development that could affect thebrain circuitryinto adulthood. ...
"Current medicine is directed at inhibiting the mammalian target of rapamycin (mTOR), a common feature within these tumors that have abnormally high activity," said David M Feliciano, assistant professor of biological sciences. "However, current treatments have severe side effects, likely due to mTO...